Investigations of the use of bioavailability data to adjust occupational exposure limits for active pharmaceutical ingredients

Toxicological Sciences

Volumn 112, Issue 1, 2009, Pages 196-210

  Naumann, Bruce D ^a   Weideman, Patricia A ^a   Sarangapani, Ramesh ^b   Hu, Shu Cheih ^c   Dixit, Rakesh ^d   Sargent, Edward V ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c IIT RESEARCH INSTITUTE   (United States)

^d MEDIMMUNE   (United States)

^e EV Sargent LLC   (United States)

Author keywords

Absorption; Bioavailability; OEL; Pharmaceutical; Respiratory tract

Indexed keywords

VERLUKAST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; EMPIRICISM; INFLAMMATION; LOWER RESPIRATORY TRACT; LUNG ALVEOLUS WALL; LUNG INFILTRATE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE CAVITY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL EXPOSURE LIMIT; PARTICLE SIZE; PNEUMONIA; POLYMORPHONUCLEAR CELL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDITY;

ANIMALS; BIOLOGICAL AVAILABILITY; LEUKOTRIENE ANTAGONISTS; MALE; OCCUPATIONAL EXPOSURE; PHARMACEUTICAL PREPARATIONS; PROPIONATES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 70849108170     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfp195     Document Type: Article

References (30)

1. Adamson, I. Y. E., Prieditis, H., and Vincent, R. (1999). Pulmonary toxicity of an atmospheric particulate sample is due to the soluble fraction. Toxicol. Appl. Pharmacol. 157, 43-50.
2. American Conference of Governmental Industrial Hygienists (ACGIH). (2008). 2009 TLVs and BEIs Based on the Documentation of the Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. American Conference of Governmental Industrial Hygienists Cincinnati, OH.
3. Andersen, M. E., Green, T., Frederick, C. B., and Bogdanffy, M. S. (2002). Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters: Assessing the state-of-knowledge and risk assessment applications with methyl methacrylate and vinyl acetate. Regul. Toxicol. Pharmacol. 36, 234-245.
4. Andersen, M. E., Sarangapani, R., Gentry, P. R., Clewell, H. J., Covington, T. R., and Frederick, C. B. (2000). Application of a hybrid CFD-PBPK nasal dosimetry model in an inhalation risk assessment: An example with acrylic acid. Toxicol. Sci. 57, 312-325.
5. Andersen, M. E., Sarangapani, R., Frederick, C. B., and Kimbell, J. S. (1999). Dosimetric adjustment factors for methyl methacrylate derived from a steady-state analysis of a physiologically based clearance-extraction model. Inhal. Toxicol. 11, 899-926.
6. Brown, R. J., and Schanker, L. (1983). Absorption of aerosolized drugs from the rat lung. Drug Metab. Dispos. 11, 355-360.
7. Byron, P. (1986). Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J. Pharm. Sci. 75, 433-438.
8. Environmental Protection Agency (EPA). (1994, October). Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/8-90/066F. U.S. EPA, Office of Research and Development, Washington, DC.
9. Gerde, P., Muggenburg, B. A., Hoover, M. D., and Henderson, R. F. (1994). Clearance of particles and lipophilic solutes from central airways. Ann. Occup. Hyg. 38(Suppl. 1), 211-214.
10. Gonda, I. (1988). Drugs administered directly into the respiratory tract: Modeling of the duration of effective drug levels. J. Pharm. Sci. 77, 340-356.
11. Gopalakrishnan, M., Suarez, S., Hickey, A. J., and Gobburu, J. V. (2005). Population pharmacokinetic-pharmacodynamic modeling of subcutaneous and pulmonary insulin in rats. J. Pharmacokinet. Pharmacodyn. 32, 485-500.
12. Hinchcliffe, M., and Illum, L. (1999). Intranasal insulin delivery and therapy. Adv. Drug Deliv. Rev. 35, 199-234.
13. Hsu, J. C. (1996). Multiple Comparisons: Theory and Methods, p. 14. Chapman and Hall, London.
14. International Commission on Radiological Protection. (ICRP). (1994). Human Respiratory Tract Model for Radiological Protection: A Report of a Task Group of the International Commission on Radiological Protection (Annals of the ICRP, publication #66, V24, nos. 1-3). Elsevier Sciences Ltd, Oxford, United Kingdom.
15. James, A., Stahlhofen, W., Rudolf, G., Egan, M., Nixon, W., Gehr, P., and Brian, K. (1991). The respiratory tract deposition model proposed by the ICRP task group. Radiat. Protection Dosimetry 38, 159-165.
16. Krishnaswami, S., Hochhaus, G., Mollmann, H., Barth, J., and Derendorg, H. (2005). Interpretation of absorption rate data for inhaled fluticasone propionate obtained in compartmental pharmacokinetic modeling. Int. J. Clin. Pharmacol. Ther. 43, 117-122.
17. Mercer, T. (1967). On the role of particle size in the dissolution of lung burdens. Health Phys. 13, 1211-1221.
18. Morrow, P. (1973). Alveolar clearance of aerosols. Arch. Int. Med. 131, 101-108.
19. Naumann, B. D., and Weideman, P. A. (1995). Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients. Hum. Ecol. Risk Assess. 1 590-613.
20. Overton, J., Jr. (1984). Physicochemical processes and the formulation of dosimetry models. Jpn J. Toxicol. Environ. Health 13, 273-294.
21. Raabe, O. G., Al-Bayati, M. A., Teague, S. V., and Rasolt, A. (1988). Regional deposition of inhaled, monodisperse, coarse and fine particles in small laboratory animals. In Inhaled Particles VI (J. Dodgson, R. I. McCallum, M. R. Bailey, and D. R. Fisher, Eds.), pp. 53-63. Pergamon Press, Oxford, United Kingdom.
22. Raabe, O. G., Yeh, H. C., Newton, G. J., Phalen, R. F., and Velasquez, D. J. (1977). Deposition of inhaled monodisperse aerosols in small rodents. In Inhaled Particles IV (W. H. Walton, Ed.), pp. 3-20. Pergamon Press, Oxford, United Kingdom.
23. Roy, M. (1989). Lung clearance modeling on the basis of physiological and biological parameters. Health Phys. 57(Suppl. 1), 255-262.
24. Sarangapani, R., and Wexler, A. S. (2000). The role of dispersion on particles deposition in the human airways. Toxicol. Sci. 54, 229-236.
25. Sargent, E. V., and Kirk, G. D. (1988). Establishing airborne exposure control limits in the pharmaceutical industry. Am. Ind. Hyg. Assoc. J. 49, 309-313.
26. Schanker, L. (1978). Drug absorption from the lung. Biochem. Pharmacol. 27, 381-385.
27. Schanker, L., Mitchell, E., and Brown, R. J. (1986). Species comparison of drug absorption from the lung after aerosol inhalation or intratracheal injection. Drug Metab. Dispos. 14, 79-88.
28. Scheuch, G., Kohlhaeufl, M. J., Brand, P., and Siekmeier, R. (2006). Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 58, 996-1008.
29. Weideman, P. A., Naumann, B. D., Shen, C. F., Thomas, J. M., Shelton, B. A., Dixit, R., and Sargent, E. V. (1997). The use of bioavailability data in setting occupational exposure limits. Toxicologist 36 169 (Abstract).
30. Widdicombe, J. (1998). Drug uptake from the airways and lungs. Indian J. Physiol. Pharmacol. 42, 3-14.